menu search

FLXN / Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8.00 per share in cash is fair to Flexion shareholders. Halper Sadeh encourages Flexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 Read More
Posted: Oct 11 2021, 12:00
Author Name: Business Wire
Views: 111568

FLXN News  

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

By Business Wire
October 11, 2021

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDA more_horizontal

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

By Business Wire
October 11, 2021

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDA more_horizontal

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

By Business Wire
October 11, 2021

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDA more_horizontal

FLXN Stock: Why It Substantially Increased Today

By Pulse2
October 11, 2021

FLXN Stock: Why It Substantially Increased Today

The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened. more_horizontal

FLXN Stock: Why It Substantially Increased Today

By Pulse2
October 11, 2021

FLXN Stock: Why It Substantially Increased Today

The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened. more_horizontal

FLXN Stock: Why It Substantially Increased Today

By Pulse2
October 11, 2021

FLXN Stock: Why It Substantially Increased Today

The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened. more_horizontal

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

By GlobeNewsWire
October 11, 2021

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain p more_horizontal

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

By GlobeNewsWire
October 11, 2021

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain p more_horizontal


Search within

Pages Search Results: